ANDA 214336, held by Aspiro. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 214336 (Lidocaine Hydrochloride), held by Aspiro, was first approved by FDA on Nov 8, 2021, with 1 approved supplement and 0 published complete response letters.
Lidocaine hydrochloride injection is indicated in adult and pediatric patients for the production of local or regional anesthesia or analgesia for surgery, dental, and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of lidocaine hydrochloride injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Lidocaine hydrochloride injection contains lidocaine, an amide local anesthetic.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 8, 2021 | Original application | Approved | None posted |
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Lidocaine Hydrochloride2% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Dec 13, 2023 | Supplement 3Manufacturing | Approved | None posted |
| Nov 8, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters